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Heart transplant (HTx) recipients have a high heart rate (HR), because of graft denervation
and are frequently started on β-blockade (BB). We assessed whether BB and HR post HTx
are associated with a specific urinary proteomic signature.
Methods
In 336 HTx patients (mean age, 56.8 years; 22.3% women), we analyzed cross-sectional
data obtained 7.3 years (median) after HTx. We recorded medication use, measured HR
during right heart catheterization, and applied capillary electrophoresis coupled with mass
spectrometry to determine the multidimensional urinary classifiers HF1 and HF2 (known to
be associated with left ventricular dysfunction), ACSP75 (acute coronary syndrome) and
CKD273 (renal dysfunction) and 48 sequenced urinary peptides revealing the parental
proteins.
Results
In adjusted analyses, HF1, HF2 and CKD273 (p 0.024) were higher in BB users than non-
users with a similar trend for ACSP75 (p = 0.06). Patients started on BB within 1 year after
HTx and non-users had similar HF1 and HF2 levels (p 0.098), whereas starting BB later
was associated with higher HF1 and HF2 compared with non-users (p 0.014). There were
no differences in the urinary biomarkers (p 0.27) according to HR. BB use was associated
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with higher urinary levels of collagen II and III fragments and non-use with higher levels of
collagen I fragments.
Conclusions
BB use, but not HR, is associated with a urinary proteomic signature that is usually associ-
ated with worse outcome, because unhealthier conditions probably lead to initiation of BB.
Starting BB early after HTx surgery might be beneficial.
Introduction
Heart transplantation (HTx) is the treatment of choice for a highly selected group of terminally ill
heart failure patients with severe symptoms not responding to optimal medical combined with
device-based therapy [1]. Denervation of the graft explains why HTx recipients commonly have a
high heart rate, which is an independent predictor of mortality [2–4]. The current study builds on
previous observations in a single-center cohort of HTx patients [5,6]. A higher heart rate 3 months
after surgery and non-use of β-blockers were associated with increased mortality [5]. In the same
cohort [6], elevated right heart pressures were associated with increased urinary levels of the mul-
tidimensional urinary classifier HF2 [7]. In line with a position paper of the American Heart Asso-
ciation supporting the use of omics technologies in research on cardiovascular disease [8], the aim
of our current study was to explore whether the use of β-blockers or tachycardia after HTx were
associated with a specific urinary peptidomic signature. We studied the multidimensional urinary
classifiers HF1 [9,10], HF2 [7], ACSP75 [11] and CKD273 [12,13], respectively consisting of 85,
671, 75 and 273 peptide fragments, mainly dysregulated peptide fragments. These markers were
developed for the diagnosis of asymptomatic diastolic left ventricular dysfunction [9,10], symp-
tomatic heart failure [7], the prediction of acute coronary events [11], and the decline in glomeru-
lar filtration rate [12,13]. We also studied single sequenced urinary peptides, which identify
parental proteins and can thereby reveal underlying pathophysiological processes.
Methods
Study participants
uPROPHET complies with the Helsinki declaration for research in humans [14]. The study
was approved by the Ethics Committee of the University Hospitals Leuven (numbers B32220
1421186 [S56384] and B322201421045 [S56472]) and passed review by the European Research
Council Executive Agency [15]. Recruitment of patients took place at the University Hospitals
Leuven in collaboration with the heart transplantation team. All HTx recipients in regular fol-
low-up at the University Hospitals Leuven gave written informed consent and provided a
5-mL mid-morning urine sample for urinary peptidomic analysis. Of the 368 patients enrolled
by the end of 2016, 336 had their heart rate measured during right cardiac catheterization
within 6 months of the urine sampling and were included in the present analysis.
Collection of clinical data
A detailed description of the construction and contents of the uPROPHET database is avail-
able elsewhere [15]. All potentially relevant clinical information, including anthropometrics,
previous medical history, biochemical measurements and use of immunosuppressive, antihy-
pertensive, lipid-lowering and antidiabetic drugs was retrieved from the computerized
Urinary proteomics after heart transplantation
PLOS ONE | https://doi.org/10.1371/journal.pone.0204439 September 24, 2018 2 / 13
Funding: The European Union (HEALTH-F7-
305507 HOMAGE; URL: http://www.homage-hf.
eu/) and the European Research Council
(Advanced Researcher Grant 2011-294713-




Research Area Net for Cardiovascular Diseases
(JTC2017-046-PROACT; URL: http://www.era-
cvd.eu/), and the Fonds voor Wetenschappelijk
Onderzoek Vlaanderen, Ministry of the Flemish
Community, Brussels, Belgium (G.0881.13; URL:
http://www.fwo.be/) currently support the
Studies Coor-dinating Centre in Leuven. Dr.
Harald Mischak and Esther Nkuipou-Kenfack
received support from the European Commission
via the SysVasc project (HEALTH FP7-603288;
URL: https://cordis.europa.eu/project/rcn/
111200_en.html). Dr. Jan Van Keer is the
recipient of a PhD researcher scholarship granted
by the Fonds voor Wetenschappelijk Onderzoek
Vlaanderen (11B3618N; URL: http://www.fwo.be/
en/). The funder provided support in the form of
salaries for authors (QFH, JVK, ZYZ, ST, WYY,
LT, FFW, JAS), but did not have any additional
role in the study design, data collection and
analysis, decision to publish, or preparation of
the manuscript. The specific roles of these
authors are articulated in the ’author
contributions’ section.
Competing interests: Harald Mischak is the
cofounder and a shareholder of Mosaiques
Diagnostics AG (Hannover, Germany). Esther
Nkuipou-Kenfack is an employee of Mosaiques
Diagnostics AG. This does not alter our adherence
to PLOS ONE policies on sharing data and
materials. None of the other authors declares a
conflict of interest.
information system of the University Hospitals Leuven. Hypertension was an office blood
pressure of at least 140 mmHg systolic or 90 mmHg diastolic or use of antihypertensive drugs.
Right heart hemodynamic measurements included mean right atrial pressure (mRAP), mean
pulmonary arterial pressure (mPAP) and mean pulmonary capillary wedge pressure
(mPCWP). The right heart pressures were averaged over the respiratory cycle. We applied the
75th percentiles of mRAP (10 mm Hg), mPAP (24 mm Hg) or mPCWP (17 mm Hg) to
define elevated right heart pressure.
Venous blood samples were drawn within one week of urine sampling after at least 8 hours of
fasting. We measured the concentration of creatinine in serum, using Jaffe’s method [16] with
modifications described elsewhere [17] and isotope-dilution mass spectrometry for calibration.
We estimated glomerular filtration rate (eGFR) from serum creatinine by the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation [18]. Diabetes mellitus was a hospital
diagnosis, a fasting plasma glucose of 126 mg/dl or higher, or use of antidiabetic agents [19].
Urinary proteomics
Methods for urine sample preparation, proteome analysis by capillary electrophoresis coupled
to mass spectrometry (CE-MS), data processing and sequencing have been published before
[15,20–22]. Peptide fragments were combined into a single summary variable, using the
MosaCluster software, version 1.7.0 [23]. The so derived multidimensional urinary classifiers
HF1 [7,9], HF2 [9], ACSP75 [11] and CKD273 [12,13] are specifically associated with or pre-
dictive of asymptomatic diastolic left ventricular dysfunction, advanced heart failure, acute
coronary syndrome or deteriorating renal function, and respectively consist of 85, 671, 75 and
273 urinary peptide fragments. They are normally distributed, higher values being associated
with worse outcomes. For in-depth analysis of individual single peptides, we selected 48 pep-
tides (S1 Table), which had a detectable signal in over 95% of participants.
Statistical analysis
For database management and statistical analysis, we used the SAS system, version 9.4 (SAS Insti-
tute Inc., Cary, NC). Means were compared using the large-sample z-test or ANOVA and propor-
tions by Fisher’s exact test. We rank normalized the distributions of the urinary peptides by
sorting measurements from the smallest to the highest and then applying the inverse cumulative
normal function [24]. We adjusted the analyses of the multidimensional classifiers for covariables,
including time since transplantation, age, mean arterial pressure, body mass index, total-to-high
density lipoprotein (HDL) cholesterol ratio, and the presence of diabetes mellitus. Analyses of
HF1, HF2 and ACSP75 were additionally adjusted for eGFR. In the last step of our analyses, we
applied partial least squares discriminant analysis (PLS-DA), which is a statistical technique that
constructs models for a categorical outcome in relation to correlated high-dimensional explana-
tory variables [25]. In our study, PLS-DA analysis allowed identifying a set of independent latent
factors that were linear combinations of the urinary peptides and that maximized the covariance
between use or non-use of β-blockers and the urinary peptides. The importance of each urinary
peptide in the construction of the PLS-DA factors was assessed from the Variable Importance in
Projection (VIP) score of Wold with the threshold set at 1.1.
Results
Patient characteristics
Among the 336 study participants, the causes of end-stage heart failure were ischemic cardio-
myopathy in 128 (38.1%), dilated cardiomyopathy in 138 (41.1%) and other etiologies in 70
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(20.8%). The urine sample for proteomics was obtained at a median interval of 7.3 years (inter-
quartile range, 2.3 to 13.8 years) after HTx. The 336 patients underwent surgery from August
1988 until October 2016 and included 75 women (22.3%). Mean (±SD) age of the donors was
36.5 ± 13.3 years. In total, 118 patients had been started on β-blockers. The indication to start
β-blockade was systemic arterial hypertension in 68 (57.6%) patients, supraventricular tachy-
cardia in 29 (24.6%), ventricular arrhythmia in 6 (5.1%), tremor in 4 (3.4%), sinus tachycardia
in 3 (2.5%), migraine in 3 (2.5%), angina pectoris in 2 (1.7%), heart failure post myocardial
infarction in 1 (0.1%), hyperthyroidism in 1 (0.1%) and not documented in 1 (0.1%). Fig 1
shows the use of β-blockers and heart rate at the time of urine collection by the time interval
since HTx. As shown in S2 Table, patients started on β-blockade within 1 year of HTx (n = 54;
45.8%), compared with those in whom β-blockade was started later (n = 64; 54.2%), were
younger (57.1 vs. 64.6 years), had lower mRAP (8.4 vs. 9.7 mm Hg) and mPAP (21.7 vs. 23.4
mm Hg) and lower serum creatinine (1.52 vs. 1.76 mg/dl) and higher eGFR (53.7 vs. 43.9 ml/
min/1.73 m2).
Table 1 lists the characteristics of the patients dichotomized by β-blocker use or the 75th
percentile of heart rate during right heart catheterization (86 beats per minute). Patients on β-
blockers compared with non-users, had a higher frequency of hypertension and diabetes melli-
tus, received their HTx a longer time ago, were older, and had higher body mass index, mPAP,
E/e’ ratio, plasma glucose, serum creatinine, but lower heart rate, serum total cholesterol,
serum HDL cholesterol and eGFR. Patients with heart rate of 86 beats per minute or higher
compared with the lower three fourths of the distribution, were leaner and had lower mRAP,
Fig 1. β-Blockers use (A) and heart rate during right heart catheterization (B) by years since heart transplantation. The number of patients contributing to each statistic
is given alongside the columns (A) or plotted points (B).
https://doi.org/10.1371/journal.pone.0204439.g001
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mPCWP and E/A ratio (Table 1). Among users of β-blockers (S3 Table), patient characteristics
did not differ between those on cardioselective agents (bisoprolol, celiprolol, metoprolol and
nebivolol) and non-cardioselective drugs (carvedilol, propranolol and sotalol). Hypertensive
compared with normotensive patients were more obese, had higher serum creatinine and
lower eGFR, but had a similar heart rate (S4 Table).
Use of medications
Of 336 patients, 67 (19.9%) were taking cyclosporine, 260 (77.4%) tacrolimus, 267 (79.5%)
mycophenolate mofetil, 20 (6.0%) azathioprine, 19 (5.7%) everolimus and 122 (36.3%)
Table 1. Baseline characteristics of participants by β-blocker use or heart rate during right heart catheterization.
Characteristic Use Non-use <86 beats/minute 86 beats/minute
Number of participants (%) 118 218 241 95
Women 23 (19.5) 52 (23.9) 54 (22.4) 21 (22.1)
Hypertension 108 (91.5) 179 (82.1) 205 (85.1) 82 (86.3)
Diabetes mellitus 37 (31.4) 46 (21.1) 59 (24.5) 24 (25.3)
Ischemic cardiomyopathy 52 (44.1) 76 (34.9) 96 (39.8) 32 (33.7)
Dilated cardiomyopathy 48 (40.7) 90 (41.3) 95 (39.4) 43 (45.3)
Elevated right heart pressure 63 (53.4) 97 (44.5) 122 (50.6) 38 (40.0)
Mean (± SD) of characteristic
Years since HTx 10.7 (4.5–15.5) 5.4 (0.9–12.0)§ 7.3 (2.7–13.5) 7.3 (0.7–14.3)
Age (years) 61.3 ± 12.0 54.4 ± 15.4§ 57.3 ± 13.9 55.6 ± 16.3
Body mass index (kg/m2) 26.1 ± 4.9 24.7 ± 3.8† 25.5 ± 4.4 24.5 ± 3.6
Systolic pressure (mm Hg) 144.1 ± 23.9 141.0 ± 19.4 142.6 ± 20.7 140.9 ± 22.2
Diastolic pressure (mm Hg) 85.7 ± 12.7 84.7 ± 10.4 85.0 ± 11.2 85.2 ± 11.4
Heart rate (beats per minute) 75.3 ± 10.4 81.3 ± 12.5§ 73.5 ± 8.3 93.6 ± 7.5§
Office heart rate (beats per minute) 77.3 ± 11.9 80.7 ± 12.5† 75.6 ± 10.7 89.4 ± 10.7§
mRAP (mm Hg) 9.1 ± 3.2 8.6 ± 2.8 9.0 ± 2.9 8.2 ± 3.1
mPAP (mm Hg) 22.6 ± 4.7 21.3 ± 4.6 22.0 ± 4.7 21.1 ± 4.6
mPCWP (mm Hg) 15.1 ± 4.5 14.1 ± 4.0 14.9 ± 4.2 13.3 ± 3.9†
Ejection fraction (%) 59.4 ± 2.4 58.9 ± 4.6 59.2 ± 4.3 58.8 ± 2.9
E/A ratio 2.28 ± 1.40 2.09 ± 1.30 2.27 ± 1.51 1.86 ± 0.67†
E/e’ ratio 6.89 ± 2.74 6.19 ± 2.07 6.58 ± 2.42 6.09 ± 2.13
Serum total cholesterol (mg/dl) 149.7 ± 34.3 159.3 ± 34.7 156.3 ± 34.2 155.0 ± 36.7
Serum HDL cholesterol (mg/dl) 53.8 ± 16.7 59.3 ± 17.1† 57.3 ± 17.4 57.6 ± 16.6
Plasma glucose (mg/dl) 106.1 ± 28.5 98.3 ± 20.8† 101.4 ± 24.5 100.0 ± 23.0
Serum creatinine (mg/dl) 1.65 ± 0.51 1.30 ± 0.43§ 1.44 ± 0.48 1.37 ± 0.51
eGFR (ml/min/1.73 m2) 48.4 ± 22.2 65.7 ± 25.1§ 57.8 ± 23.5 64.2 ± 29.6
Abbreviations: mRAP, mean right atrial pressure; mPAP, mean pulmonary arterial pressure; mPCWP, mean pulmonary capillary wedge pressure; HDL, high-density
lipoprotein; eGFR, glomerular filtration rate estimated from serum creatinine. Heart rate refers to the heart rate measured during right heart catheterization. A heart
rate of 86 during right heart catheterization corresponded to the 75th percentile of the distribution. Office heart rate was measured on the day of the urine collection
within 6 months of the catheterization. For years since transplantation the median (interquartile range) is given. Hypertension was an office blood pressure of at least
140 mmHg systolic or 90 mmHg diastolic or use of antihypertensive drugs. Diabetes mellitus was a hospital diagnosis, a fasting plasma glucose of 126 mg/dl or higher,
or use of antidiabetic agents. Elevated right heart pressure was mRAP (10 mm Hg), mPAP (24 mm Hg), or mPCWP (17 mm Hg) equal to or exceeding the 75th
percentile of the distributions.
Significance of the between-group difference
 p  0.05
† p  0.01
§ p  0.0001.
https://doi.org/10.1371/journal.pone.0204439.t001
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methylprednisolone. Sixteen (4.8%) were taking a single immunosuppressant, 221 (65.8%) two
drugs and 99 (29.5%) three drugs. The most common combination was tacrolimus plus myco-
phenolate mofetil (209 patients; 62.2%). The number of patients taking one or more blood
pressure lowering drugs was 240 (71.4%), of whom 66 (27.5%) were on a thiazide or a loop
diuretic, 118 (35.1%) on β-blockers, 148 (61.7%) on angiotensin-converting enzyme inhibitors
or angiotensin I receptor blockers, 99 (41.3%) on calcium-channel blockers and 20 (8.3%) on
aldosterone antagonists. The number of patients on antidiabetic treatment totaled 88, of
whom 53 (60.2%) were on oral therapy and 35 (39.8%) on insulin.
β-Blockers users vs. non-users (Table 2) were less frequently taking tacrolimus (67.8% vs.
82.6%), but were more frequently treated with cyclosporine (29.7% vs. 14.7%), thiazides
(17.8% vs. 6.4%), inhibitors of the renin-angiotensin system (54.2% vs. 38.5%) and insulin
(16.1% vs. 7.3%). The differences in medication use between patients with fast vs. slow heart
rate were all nonsignificant except for the use of β-blockers (Table 2).
Multidimensional classifiers
We adjusted the analyses for time since transplantation, age, mean arterial pressure, body
mass index, total-to-HDL cholesterol ratio, and the presence of diabetes mellitus. Analyses of
Table 2. Use of medications by β-blocker use or heart rate during right heart catheterization.
Characteristic Use Non-use <86 beats/minute 86 beats/minute
Number of participants (%) 118 218 241 95
Immunosuppressive treatment
Calcineurin inhibitor 115 (97.5) 212 (97.3) 233 (96.7) 94 (99.0)
Tacrolimus 80 (67.8) 180 (82.6)† 189 (78.4) 71 (74.7)
Cyclosporine 35 (29.7) 32 (14.7)‡ 44 (18.3) 23 (24.2)
Antiproliferative agents 98 (83.1) 189 (86.7) 205 (85.1) 82 (86.3)
mTOR inhibitors 8 (6.8) 11 (5.1) 12 (5.0) 7 (7.4)
Methylprednisolone 42 (35.6) 80 (36.7) 82 (34.0) 40 (42.1)
Antihypertensive drugs
Any drug class 100 (84.8) 140 (64.2)§ 173 (71.8) 67 (70.5)
β-blockers 118 (100) 0 (0) . . . 95 (39.4) 23 (24.2)†
Thiazides 21 (17.8) 14 (6.4)‡ 29 (12.0) 6 (6.3)
Loop diuretics 10 (8.5) 24 (11.0) 25 (10.4) 9 (9.5)
Aldosterone antagonists 4 (3.4) 16 (7.3) 14 (5.8) 6 (6.3)
Calcium channel blockers 31 (26.3) 68 (31.2) 70 (29.1) 29 (30.5)
RAS inhibitors 64 (54.2) 84 (38.5)† 110 (45.6) 38 (40.0)
Use of statins 112 (94.9) 202 (92.7) 222 (92.1) 92 (96.8)
Use of antidiabetic drugs
Insulin 19 (16.1) 16 (7.3) 25 (10.4) 10 (10.5)
Other agents 22 (18.6) 31 (14.2) 39 (16.2) 14 (14.7)
Abbreviations: mTOR, mammalian target of rapamycin; RAS renin-angiotensin system. Drugs by class: calcineurin inhibitors, tacrolimus and cyclosporine;
antiproliferative agents, azathioprine and mycophenolate mofetil; mTOR inhibitors, everolimus and sirolimus; RAS inhibitors, converting-enzyme inhibitors and
angiotensin II type-1 receptor blockers. A heart rate of 86 during right heart catheterization corresponded to the 75th percentile of the distribution.
Significance of the between-group differences: . . .
p not computed
 p  0.05
† p  0.01
‡ p  0.001
§ p  0.0001.
https://doi.org/10.1371/journal.pone.0204439.t002
Urinary proteomics after heart transplantation
PLOS ONE | https://doi.org/10.1371/journal.pone.0204439 September 24, 2018 6 / 13
HF1, HF2 and ACSP75 were additionally adjusted for eGFR. With such adjustments applied
(Table 3), levels of HF1, HF2 and CKD273 were significantly (p 0.024) higher in β-blockers
users compared with non-users with a similar trend for ACSP75 (p = 0.060). In contrast, there
were no differences in the levels of these urinary classifiers (p 0.27) by category of heart rate
(Table 3). In similarly adjusted models including both β-blocker use vs. non-use and heart rate
category, all four classifiers were higher in β-blocker users compared with non-users
(p 0.045) with no differences (p 0.16) between the heart rate categories (Table 3). Sensitiv-
ity analyses additionally adjusted for elevated right heart pressure (0,1), the use of antihyper-
tensive drugs other than β-blockers (0,1) and immunosuppressants (by drug class) were
confirmatory.
β-Blockade was initiated at a median interval of 1.7 years (interquartile range, 0.3 to 6.0
years) after HTx. For HF1 and HF2, but not for ACSP75 and CKD273, there was a time trend
associated with early (within 1 year after HTx; n = 54) vs. later (n = 64) start of β-blockade (Fig
2). The indications for starting β-blockade were similar (p = 0.58) in patients started early vs.
later.
Sequenced urinary peptides
The PLS-DA analyses yielded two latent factors that accounted for 26.9% of the overall vari-
ance in the urinary peptides and 18.4% of the variance in use vs. non-use of β-blockers. Fig 3
depicts the PLS-DA derived Variance in Projection (VIP) scores vs. the centered and rescaled
correlation coefficients. VIP scores indicate the importance of each urinary fragment in the
construction of the partial least square factors. The correlation coefficients reflect the associa-
tions of β-blocker use vs. non-use with the urinary fragments. The urinary peptides associated
with non-use of β-blockers (left side of the V plot) included collagen I fragments (p32171,
p35339, p43442, p44618, p63910 and p72596). The urinary peptides associated with use of β-
blockers included fragments of collagen II (p16976 and p41431) and III (p61332, p98660 and
P105352) and a fragment of collagen IV (p99577), the fibrinogen α chain (p64256) and the
mucin-1 subunit α (p8342).
Table 3. Urinary levels of classifiers by β-blocker use or heart rate during right heart catheterization.
Model
Classifier
β-blocker use vs. non-use Heart rate categories
Use Non-use Δ (95% CI) p <86 bpm 86 bpm Δ (95% CI) p
Adjusted
HF1 –0.53 ± 0.09 –0.78 ± 0.06 –0.25 (–0.46, –0.03) 0.024 –0.68 ± 0.06 –0.72 ± 0.09 0.04 (–0.18, 0.25) 0.73
HF2 0.07 ± 0.06 –0.12 ± 0.04 –0.19 (–0.34, –0.05) 0.009 –0.08 ± 0.04 0.00 ± 0.06 –0.08 (–0.23, 0.06) 0.27
ACSP75 0.47 ± 0.24 –0.11 ± 0.18 –0.59 (–1.20, 0.02) 0.060 0.00 ± 0.16 0.33 ± 0.26 –0.33 (–0.94, 0.28) 0.29
CKD273 0.19 ± 0.04 0.07 ± 0.03 –0.12 (–0.21, –0.02) 0.017 0.12 ± 0.03 0.07 ± 0.04 0.05 (–0.05, 0.15) 0.31
Mutually
adjusted
HF1 –0.53 ± 0.09 –0.78 ± 0.06 –0.24 (–0.46, –0.03) 0.026 –0.65 ± 0.06 –0.66 ± 0.09 0.01 (–0.20, 0.23) 0.92
HF2 0.10 ± 0.06 –0.10 ± 0.04 –0.20 (–0.35, –0.06) 0.006 –0.05 ± 0.04 0.05 ± 0.06 –0.10 (–0.25, 0.04) 0.16
ACSP75 0.58 ± 0.26 –0.04 ± 0.18 –0.63 (–1.24, –0.01) 0.045 0.07 ± 0.17 0.47 ± 0.27 –0.40 (–1.01, 0.21) 0.20
CKD273 0.17 ± 0.04 0.06 ± 0.03 –0.11 (–0.21, –0.02) 0.023 0.14 ± 0.03 0.10 ± 0.04 0.04 (–0.06, 0.13) 0.47
Values are mean ± SE or mean between-group differences (Δ) with 95% confidence interval (95% CI). All models were adjusted for time since transplantation, age,
mean arterial pressure, body mass index, total-to-HDL cholesterol ratio and the presence of diabetes mellitus. For HF1, HF2 and ACSP75, models were additionally
adjusted for glomerular filtration rate estimated from serum creatinine. Mutually adjusted models included both β-blocker use vs. non-use and heart rate during right
heart catheterization categorized by 86 beats per minute (bpm), the 75th percentile of the distribution.
https://doi.org/10.1371/journal.pone.0204439.t003
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Sensitivity analyses
The correlation between heart rate during right heart catheterization and office heart rate at
the time of the urine collection was 0.68 (p< 0.0001). Replacing heart rate during right heart
catheterization by office heart rate therefore produced consistent results (S5–S7 Tables).
We ran an additional analysis dictomized according to whether or not patients were on
inhibitors of the renin-angiotensin system. As before, we adjusted these analyses for time since
transplantation, age, heart rate, mean arterial pressure, body mass index, total-to-HDL choles-
terol ratio, and the presence of diabetes mellitus. The analyses of HF1, HF2 and ACSP75 were
additionally adjusted for eGFR. With these adjustments applied, levels of HF1, HF2, ACSP75
and CKD273 were significantly (p 0.046) higher in users of inhibitors of the renin-angioten-
sin system compared with non-users (S8 Table).
Discussion
The key finding of our manuscript was that use vs. non-use of β-blockers was associated with
specific urinary proteomic signatures, whereas heart rate was not (Table 3). β-blocker use cor-
related with higher levels of the multidimensional classifiers HF1, HF2, ACSP75 and CKD273,
which in other studies were indicative of a worse haemodynamic condition [7] or predicted
cardiovascular [26], cardiac [26] or coronary [11] events or decline in renal function [12,27].
Along similar lines, β-blockade was associated with higher levels of various fragments of colla-
gen II and III and a fragment of the fibrinogen α chain and the mucin-1 subunit α, which are
indicative of diastolic left ventricular dysfunction [28] or renal impairment [13,27]. These
observations probably reflect reverse causality, indicating that unhealthier HTx patients, as
reflected by their urinary biomarkers, were more likely to be started on a β-blocker. In keeping
with this idea, patients on β-blockers compared with non-users, had a higher frequency of
hypertension and diabetes mellitus, were older and more obese, and had lower eGFR
(Table 1).
Fig 2. Levels of the urinary classifiers HF1 and HF2 in non-users of β-blockers and in users started on β-blockade within 1 year of
heart transplantation (n = 54) or later (n = 64). Estimates given with SE were adjusted for time since transplantation, age, mean arterial
pressure, body mass index, total-to-HDL cholesterol ratio, glomerular filtration rate estimated from serum creatinine and the presence of
diabetes mellitus. p values denote the significance of the difference between non-users and users.
https://doi.org/10.1371/journal.pone.0204439.g002
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For HF1 and HF2 there was a time trend associated with the start of β-blockade (Fig 2),
which were adjusted for confounders as patients in whom beta blockers were initiated within
one year had favorable risk profile shown in S2 Table. Patients started on β-blockers early after
HTx had HF1 and HF2 levels not different from those in non-users, whereas in patients started
on β-blockers 1 year after HTx HF1 and HF2 levels were significantly higher than in non-
users. These observations are in line with our previous report [5], in which all-cause mortality
was studied in relation to heart rate during right heart catheterization and use of β-blockers at
3 months after HTx. The study included 461 HTx patients with a mean follow-up of 11.9
years. Patients receiving β-blockers had lower mortality than those who did not use β-blockers
Fig 3. V-plots generated by partial least squares discriminant analysis. Variable Importance in Projection (VIP) scores
indicate the importance of each urinary fragment in the construction of the partial least squares factors and are plotted against
the centered and rescaled correlation coefficients. These correlation coefficients reflect the associations of β-blockers use vs.
non-use with the urinary fragments. The urinary peptides associated with non-use (left side of the V plot) included collagen I
fragments. The urinary peptides associated with use of β-blockers included fragments of collagen II and III and a fragment of
collagen IV, the fibrinogen α chain and the mucin-1 subunit α. Colors identify fragments derived from collagen I (blue), II
(grey), III (red), IV (brown), V (pink), mucin-1 subunit α (orange), fibrinogen (green), and uromodulin (black).
https://doi.org/10.1371/journal.pone.0204439.g003
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[5]. In multivariable-adjusted analyses, older age, longer hospitalization, higher mPAP, higher
heart rate at 3 months (hazard ratio [HR], 1.22 per 10 beats per minute; p = 0.02) and use vs.
non-use of β-blockers (HR, 1.43; p = 0.05) predicted higher mortality [5]. Survival function
analysis demonstrated that β-blockade delayed death up to 15 years after transplantation
(p = 0.04), whereafter the survival curves between user and non-users of β-blockers coincided.
To our knowledge, no other study described the early protective effect of β-blockade in HTx
patients. Our current observations (Fig 2) and this report [5] suggest that starting β-blockade
early in HTx patients might be protective over and beyond lowering of heart rate, a hypothesis
worth testing in a randomized clinical trial.
High heart rate is an independent predictor of mortality both in the general population [29]
and HTx recipients [2–4]. Whether or not β-blockade confers benefit in patients with cardio-
vascular disease remains controversial [30–32]. In the Reduction of Atherothrombosis for
Continued Health (REACH) registry, propensity score matching was used for the primary
analyses involving 21,860 patients with a median follow-up of 44 months. Event rates were not
significantly different in patients on β-blockers compared with those not on β-blockers for any
of the outcomes tested, even in the prior myocardial infarction cohort (HR, 0.90; p = 0.14)
[31]. A meta-analysis [32] including 17,397 patients with coronary heart disease without previ-
ous myocardial infarction or reduced ejection fraction, showed that β-blocker use did not
entail any reduction in all-cause mortality (odds ratio [OR] 0.91; p = 0.16) or cardiac mortality
(OR, 0.93; p = 0.41). However, double-blind placebo-controlled trials of β-blocker use after
myocardial infarction published more than 30 year ago [30], in contrast to the more recent
observational studies [31,32], demonstrated substantial benefit of β-blockade in secondary
prevention.
In an earlier published population study (n = 782), a 1-SD increment in a urinary collagen I
fragment was associated with 0.183 cm/s (p = 0.025) lower e’ (peak velocity of the mitral annu-
lar movement in early diastole) and 0.210 cm/s (p = 0.0012) greater E/e’ (peak velocity of the
transmitral blood flow in early diastole divided by e’) [28]. E/e’ decreased by 0.168 (p = 0.018)
in relation to a urinary fragment of collagen III [28]. Lower e’ and higher E/e’ reflect worse dia-
stolic left ventricular function. In heart failure patients, β-blockers inhibit the myocardial deg-
radation of collagen [33,34], possibly via a transforming growth factor β1-mediated
mechanism [33]. These observations [33,34], and the differences in the hemodynamic condi-
tions leading to the initiation of β-blockade (Table 1) might partially explain why in our cur-
rent study β-blockade was associated with higher urinary levels of collagen III fragments and
non-use with higher levels of collagen I (Fig 3).
Our study must be interpreted within the context of its limitations. First, our analysis was
cross-sectional. However, we ascertained that over the interval from initiation of β-blockade
until the assessment of the urinary proteome all 118 patients started on a β-blocker continued
their treatment. Second, our study was a single-center study so that the generalizability of our
observations remains to be confirmed in other HTx cohorts. Third, the observational nature of
our findings does not allow making causal interferences. Finally, although we adjusted for
known confounders, prescription of any drug, including β-blockers during follow-up of heart
transplant recipients, is necessarily biased, which may confound the results to an extent that
cannot be fully appreciated. However, the sensitivity analysis of inhibitors of the renin-angio-
tensin system supported our hypothesis that reverse causality explained the association
between β-blockade and the urinary biomarkers. Unfortunately, we did not collect urine sam-
ples prior to the initiation of β-blockade or inhibitors of the renin angiotensin system, so that
we could not assess the changes in the urinary biomarker profile induced by these drugs.
In conclusion, in HTx recipients, use of β-blockers vs. non-use, but not heart rate, is associ-
ated with a specific urinary proteomic signature that includes multidimensional classifiers and
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urinary fragments of collagen and other proteins, usually associated with adverse health out-
comes [7,11,12,26–28]. Reverse causality probably explains these findings. The urinary levels
of the multidimensional classifiers HF1 and HF2 reportedly associated with worse left ventric-
ular function in the general population [7] or increased right heart pressures in HTx patients
[6], increased with later post-surgery initiation of β-blockade. This finding along with our pre-
vious report [5], suggest that there might be benefit in starting a β-blocker soon after surgery
in all HTx patients, but this hypothesis remains to be confirmed in a randomized clinical trial.
Supporting information
S1 Table. Urinary peptide fragments with known amino acid sequence.
(DOC)
S2 Table. Baseline characteristics of participants by starting year of β-blockade.
(DOC)
S3 Table. Baseline characteristics of participants by type of β-blockers.
(DOC)
S4 Table. Baseline characteristics of participants by blood pressure category.
(DOC)
S5 Table. Baseline characteristics of participants by β-blocker use or office heart rate.
(DOCX)
S6 Table. Use of medications by β-blocker use or office heart rate.
(DOCX)
S7 Table. Urinary levels of classifiers by β-blocker use or office heart rate.
(DOCX)
S8 Table. Urinary levels of classifiers by RAS inhibitor use.
(DOCX)
Acknowledgments
The authors gratefully acknowledge the expert clerical assistance of Vera De Leebeeck and
Renilde Wolfs.
Author Contributions
Conceptualization: Jan A. Staessen.
Data curation: Qi-Fang Huang, Jan Van Keer, Sander Trenson, Lucas N. L. Van Aelst.
Formal analysis: Qi-Fang Huang, Zhen-Yu Zhang, Lutgarde Thijs.
Funding acquisition: Jan A. Staessen.
Investigation: Qi-Fang Huang, Jan Van Keer, Zhen-Yu Zhang, Wen-Yi Yang, Fang-Fei Wei.
Methodology: Esther Nkuipou-Kenfack, Harald Mischak, Jan A. Staessen.
Project administration: Jan A. Staessen.
Resources: Jan A. Staessen.
Software: Lutgarde Thijs.
Urinary proteomics after heart transplantation
PLOS ONE | https://doi.org/10.1371/journal.pone.0204439 September 24, 2018 11 / 13
Supervision: Agnieszka Ciarka, Johan Vanhaecke, Stefan Janssens, Johan Van Cleemput, Har-
ald Mischak, Jan A. Staessen.
Validation: Jan A. Staessen.
Visualization: Qi-Fang Huang, Zhen-Yu Zhang, Wen-Yi Yang, Fang-Fei Wei.
Writing – original draft: Qi-Fang Huang, Jan A. Staessen.
Writing – review & editing: Qi-Fang Huang, Jan Van Keer, Zhen-Yu Zhang, Sander Trenson,
Esther Nkuipou-Kenfack, Lucas N. L. Van Aelst, Wen-Yi Yang, Lutgarde Thijs, Fang-Fei
Wei, Agnieszka Ciarka, Johan Vanhaecke, Stefan Janssens, Johan Van Cleemput, Harald
Mischak, Jan A. Staessen.
References
1. Haddad H, Isaac D, Legare JF, Pflugfelder P, Hendry P, Chan M et al. Canadian Cardiovascular Society
Consensus Conference update on cardiac transplantation 2008: Executive Summary. Can J Cardiol.
2009; 25: 197–205. PMID: 19340342
2. Castel M, Roig E, Rios J, Tomas C, Mirabet S, Cardona M et al. Long-term prognostic value of elevated
heart rate one year after heart transplantation. Int J Cardiol. 2013; 168: 2003–7. https://doi.org/10.
1016/j.ijcard.2012.12.089 PMID: 23336956
3. Wachter SB, McCandless SP, Gilbert EM, Stoddard GJ, Kfoury AG, Reid BB et al. Elevated resting
heart rate in heart transplant recipients: innocent bystander or adverse prognostic indicator? Clin Trans-
plant. 2015; 29: 829–34. https://doi.org/10.1111/ctr.12587 PMID: 26171948
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